首页> 外文学位 >The role of CD40-CD40 ligand interactions in transplantation.
【24h】

The role of CD40-CD40 ligand interactions in transplantation.

机译:CD40-CD40配体相互作用在移植中的作用。

获取原文
获取原文并翻译 | 示例

摘要

The major obstacle still facing long-term graft acceptance is the strong T cell mediated immune response directed at the graft. Currently administered immunosuppressive regimens cause severe side effects most notably systemic immunosuppression. Therefore, an ideal immunosuppressive therapy would be one that's administered during the inductive phase of T cell activation and target alloreactive T cells. Blockade of the CD40-CD40L T cell costimulatory pathway is a promising target for inducing transplantation tolerance. Thus, the focus of this dissertation was to further elucidate the role of CD40-CD40L interactions in transplantation. This question was addressed through (1) The use of CD40−/− allograft recipients and donors and (2) Treatment of WT cardiac allograft recipients with anti-CD40L mAb therapy.; CD40-CD4OL interactions were not requisite for allograft rejection, in that CD40−/− BALB/c and CD40−/− C57BL/6 recipients rejected CD40−/− allografts. However, further analysis revealed that the ability of CD40−/− recipients to reject WT allografts was strain specific. Immunologic assessment revealed that Thl priming was markedly inhibited in CD40−/− C57BL/6 recipients that rejected their grafts compared to WT C57BIJ6 recipients.Anti-CD40L blockade prolonged allograft survival in CD40−/−; C57BL/6 recipients of CD40−/− allografts, but not CD40−/−-BALB/c recipients. Finally, CD40-CD40L independent CD8+ T cells appear to be required for rejection mediated in CD40−/− recipients.; Inductive treatment of WT cardiac allograft recipients with anti-CD40L was effective at prolonging allograft survival, which is not associated with a deletion of donor-reactive IL-2 producing helper, cytolytic or IFNγ producing T cells. These mice retained the ability to reject donor strain skin allografts, but failed to reject the original cardiac allograft or a second donor strain cardiac allograft. Further characterization of cells obtained from mice bearing long-term cardiac allografts demonstrated that longterm graft acceptance was not associated with decreased immunogenicity of the original cardiac allograft A series of adoptive transfer experiments utilizing mice bearing longterm cardiac allografts suggested the presence of a putative regulatory cell population following inductive anti-CD40L blockade. In vitro and in vivo analysis indicated that anti-CD40L therapy induced IL-10 producing regulatory cells that controlled III responsiveness. However, anti-IL-10 treatment Med to ablate long-term graft acceptance induced by anti-CD40L therapy. Collectively these data suggest the presence of an IL-10 producing regulatory cell population that is involved in maintaining long-term graft acceptance following inductive anti-CD40L therapy.
机译:长期接受移植物仍面临的主要障碍是针对移植物的强T细胞介导的免疫反应。当前施用的免疫抑制方案引起严重的副作用,最明显的是全身性免疫抑制。因此,理想的免疫抑制疗法应是在T细胞活化的诱导阶段和靶向同种异体反应性T细胞的过程中进行治疗。 CD40-CD40L T细胞共刺激途径的封锁是诱导移植耐受的有希望的目标。因此,本论文的重点是进一步阐明CD40-CD40L相互作用在移植中的作用。 (1)使用CD40-/-同种异体移植受者和供体,以及(2)用抗CD40L mAb治疗治疗WT心脏同种异体移植受者。 CD40-CD4OL相互作用对于同种异体移植不是必需的,因为CD40-/-BALB / c和CD40-/-C57BL / 6受者拒绝了CD40-/-同种异体移植。然而,进一步的分析表明,CD40-/-受体拒绝WT同种异体移植物的能力是菌株特异性的。免疫学评估显示,与野生型C57BIJ6受体相比,拒绝移植的CD40-/-C57BL / 6受体显着抑制了Thl启动。抗CD40L阻断可延长同种异体移植在CD40-/-中的存活。 CD40-/-同种异体移植的C57BL / 6受体,但CD40-/-BALB / c受体无。最后,CD40-/-CD40L独立的CD8 + T细胞似乎是CD40-/-受体介导的排斥反应所必需的。用抗CD40L诱导治疗WT心脏同种异体移植受体可有效延长同种异体移植存活时间,这与删除供体反应性产生IL-2的辅助细胞,溶细胞性或IFNγ产生性T细胞无关。这些小鼠保留了拒绝供体菌株皮肤同种异体移植物的能力,但是不能拒绝原始的心脏同种异体移植物或第二个供体菌株心脏同种异体移植物。从具有长期心脏同种异体移植物的小鼠获得的细胞的进一步表征表明,长期移植物的接受与原始心脏异体移植物的免疫原性降低无关。利用具有长期心脏同种异体移植物的小鼠的一系列过继转移实验表明存在假定的调节细胞群诱导性抗CD40L封锁。 体外体内分析表明,抗CD40L疗法可诱导IL-10产生调控III反应性的调节细胞。但是,抗IL-10治疗可减轻抗CD40L治疗引起的长期移植物接受。这些数据共同表明存在诱导产生IL-10的调节细胞群,该细胞群参与诱导抗CD40L治疗后维持长期移植物接受。

著录项

  • 作者

    Nathan, Meera J.;

  • 作者单位

    University of Michigan.;

  • 授予单位 University of Michigan.;
  • 学科 Health Sciences Immunology.
  • 学位 Ph.D.
  • 年度 2001
  • 页码 185 p.
  • 总页数 185
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 预防医学、卫生学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号